Newsletter December | Philips Healthcare

December 2017

In this issue

• Consider every breath: AVAPS therapy & the chronic disease

• Tech Spotlight: Philips InnoSpire Go portable nebulizer

• Happenings: Philips & World COPD Day 2017

Consider every breath: AVAPS therapy & the chronic disease sufferer

Average Volume Assured Pressure Support (AVAPS) therapy technology¹ is designed to provide consistent tidal volume – e.g. volume of inhaled air – at the lowest minimum inspiratory pressure. AVAPS therapy maintains the low pressure required to achieve the prescribed tidal volume, with each and every breath. Patients can enjoy enhanced comfort and the confidence that the therapy is working effectively.

This article explores how hybrid mode AVAPS can be an effective therapy for chronic disease sufferers, whose disease progression and needs evolve.

Tell us what you think

Happenings

Philips & World COPD Day 2017: there’s always a way to make life better

Chronic obstructive pulmonary disease (COPD) is a common, often underdiagnosed, and debilitating disease. It is fourth leading cause of death worldwide and is estimated to be the third leading cause by 2020², and yet, there is still a lack of awareness and a social stigma associated with the disease.

Philips is committed to sustaining the education and moral support of patients, families and care givers impacted by COPD. Recently Philips joined forces with the Global Initiative for Chronic Obstructive Lung Disease (GOLD) to support World COPD Day.

This year, Philips joined forces with with Russell Winwood and his physician to help educate, engage and empower COPD patients and their caregivers. Russell Winwood, a COPD patient and advocate, shares his personal journey with other COPD patients to inspire them to live their lives to the fullest.

Tech Spotlight

InnoSpire Go. More time for life.

Philips InnoSpire Go is a virtually silent, handheld nebulizer designed as a fast, convenient, and portable treatment option for the rising population of both children and adults with chronic respiratory conditions. InnoSpire Go simplifies the delivery of inhaled medication, offering fast and effective four-minute treatment³, reducing treatment time by 25%^4.

Learn more

Stay up to date with CME

Access new sleep and respiratory continuing medical education on the CHEST^® Journal website (CHEST links require login) in the CHEST® CME Resource Center

Available now:

COPD HOT HMV: Improving Admission-Free Survival in Persistent Hypercapnic COPD

New Editorial

¹BiPAP AVAPS only

²Global Initiative for Chronic Obstructive Lung Disease. 2017. Retrieved from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd

³Using 2.5ml Salbutamol. Data on file.

⁴Versus predecessor, Aeroneb Go. Data on file.

Sleep & Respiratory Newsletter